01 / Contract Profile
W81XWH16C0162 Federal Contract Award
Agency code 2100
RESEARCH AND DEVELOPMENT CONTRACT ENTITLED: CLINICAL TRIALS INVOLVING SOLVENT DETERGENT SPRAY DRIED PLASMA FOR REVERSAL OF COAGULOPATHY.
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
W81XWH16C0162 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
Latest fiscal year obligations-$2.02M
FY 2024Net obligationsComplete recorded range
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2016 | $9.92M | 2 | — |
| FY 2017 | -$2.97M | 4 | −129.9% |
| FY 2018 | $3.19M | 4 | +207.4% |
| FY 2019 | $10.23M | 4 | +221.2% |
| FY 2020 | $0 | 1 | −100.0% |
| FY 2021 | -$22.2K | 2 | — |
| FY 2022 | -$86.3K | 2 | −288.5% |
| FY 2024 | -$2.02M | 1 | −2,239.5% |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| DEPT OF DEFENSE | DEPT OF THE ARMY | W4PZ USA MED RSCH ACQUIS ACT |
05 / Contractor
Who holds this federal contract?
ENTEGRION, INC.
UEI LLK3BJBGY2J5 · CAGE 37RF4
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541712 | RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) | $18.25M | 20 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| AN22 | R&D- MEDICAL: DRUG DEPENDENCY (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT) | $18.25M | 20 | 100.0% |
08 / Place of Performance
Where is the work recorded?
DURHAM, DURHAM, NORTH CAROLINA, UNITED STATES
ZIP 277099998
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Feb 13, 2024 | P00019 | -$2.02M | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Jul 26, 2022 | P00018 | -$86.3K | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| May 18, 2022 | P00017 | -$0 | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Aug 11, 2021 | P00016 | -$22.2K | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Feb 1, 2021 | P00015 | $0 | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Mar 27, 2020 | P00014 | $0 | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Sep 16, 2019 | P00013 | $0 | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Jul 19, 2019 | P00012 | $3.95M | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Apr 24, 2019 | P00011 | $3.30M | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Jan 11, 2019 | P00010 | $2.98M | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Sep 20, 2018 | P00009 | $1.44M | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Aug 17, 2018 | P00008 | $746.5K | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Apr 20, 2018 | P00007 | $1.00M | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Mar 27, 2018 | P00006 | $0 | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
| Aug 25, 2017 | P00005 | -$2.97M | W4PZ USA MED RSCH ACQUIS ACTOffice code W81XWH | 541712 | AN22 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.